News

MultivisionDx has raised a €1M pre-seed funding round to accelerate the development of the company’s spatial biology diagnostics platform, an award-winning technology that matches cancer patients to the best treatments for the biology of their disease.

The MultivisionDx board of directors has appointed Michael Wittinger as the new CEO of the company.

The scientific publication describing the proof-of-concept of MultivisionDx technology has been selected for this year’s Medix Prize..

Many cancer patients go through several ineffective treatments – but what if the trial and error could be skipped?💡.

MultivisionDx was selected as the Health and Wellbeing winner at the Maria 01 NOW Pitching Competition in Helsinki..

MultivisionDx,News a spinout company from the University of Helsinki..

MultivisionDx Data Science Lead Fabien Bertillot wins clinical impact prize at Owkin/Servier glioblastoma hackathon..

An international team of researchers led by Sara Wickström has now developed a new technique..